Skip to content

Prospective clinical trial to elucidate the association between symptomatic atrial fibrillation and arterial stiffness and analysis of its clinical relevance

Prospective clinical trial to elucidate the association between symptomatic atrial fibrillation and arterial stiffness and analysis of its clinical relevance - PANDA (Perception of Atrial Fibrillation iN Dependence of Arterial Stiffness)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00019007
Enrollment
170
Registered
2019-11-14
Start date
2017-03-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Personality trait Perception Recurrence I48

Interventions

Group 1: Asymptomatic to oligosymptomatic patients (EHRA I-IIa). Within the clincial routine a transesophageal echocardiography procedure was performed before cardioversion/ pulmonary vein isolation

Sponsors

Universitätsklinikum Mannheim
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: male and female pts = 18 years, with atrial fibrillation, written informed consent

Exclusion criteria

Exclusion criteria: Unstable Angina pectoris / Acute Myocardial Infarction / Cardiogenic Shock Indications for operative coronary revascularization (bypass surgery) Stroke or TIA Resting heart rate <50 beats per minute Presence of a pacemaker / AICD and other metallic implants Valve vitium with indication for surgery Sick sinus syndrome, SA block, AV block III Uncontrolled hypertension Severe hypotension (<90 / 50mmHg) Severe hepatic insufficiency Patients with heart failure NYHA class III - IV Pacemaker dependency

Design outcomes

Primary

MeasureTime frame
Clinical symptoms (measurement method: questionnaire, interview) Aortic distensibility (measurement method: echocardiography transthoracic / transesophageal) Pulse wave velocity and augmentation index (measurement method: pulse wave analysis using a tonometrically recorded pulse curve). The primary endpoint is collected only once at the beginning of the study.

Secondary

MeasureTime frame
Laboratory measured parameters for oxidative stress and inflammation (50 ml blood, 3xLi-Hep, 3xCitrate, 3xEDTA): VCAM-1, ICAM-1, MCP-1, TNF-alpha, IL-6, hs-CRP (measurement method: ELISA) Personality trait (measurement method: questionnaire 5 BT, interview). The secondary endpoint is collected only once at the beginning of the study.

Countries

Germany

Contacts

Public ContactAnna Hohneck

Universitätsklinikum Mannheim I. Medizinische Klinik - Kardiologie

annalena.hohneck@umm.de0621-383 2204

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 26, 2026